683 Capital Management’s Viridian Therapeutics VRDN Stock Holding History

683 Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18,265	Closed	-$338K	–	332
2022 Q1	$338K	Sell	18,265 -3,363	-16%	-$64.6K	0.02%	218
2021 Q4	$428K	Buy	+21,628	New	+$403K	0.02%	218
2020 Q1	–	Sell	-19,333	Closed	-$139K	–	192
2019 Q4	$139K	Sell	19,333 -98,403	-84%	-$1.01M	0.02%	141
2019 Q3	$1.29M	Hold	117,736	–	–	0.21%	75
2019 Q2	$3.62M	Hold	117,736	–	–	0.47%	64
2019 Q1	$4.93M	Buy	117,736 +4,600	+4%	+$208K	0.66%	50
2018 Q4	$5.14M	Buy	+113,136	New	+$6.54M	0.76%	56
2018 Q3	–	Sell	-33,333	Closed	-$3.21M	–	194
2018 Q2	$3.21M	Hold	33,333	–	–	0.42%	67
2018 Q1	$3.5M	Buy	+33,333	New	+$3.62M	0.52%	67

Other funds holding VRDN

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return